Gene therapy using an integrating vector Allogeneic hematopoietic stem cell transplant at any time not permitted
Prior allogeneic hematopoietic cell transplant
Prior allogeneic hematopoietic cell transplant
Previous allogeneic hematopoietic stem cell transplant
Prior allogeneic hematopoietic stem cell transplants
Allogeneic hematopoietic stem cell transplant
Prior allogeneic transplant for any hematopoietic disorder
Patients who have undergone a prior allogeneic hematopoietic or (other organ) transplant
Previous allogeneic hematopoietic cell transplant (HCT)
Has previously received an allogeneic hematopoietic cell transplant or chimeric antigen receptor-modified (CAR)-T cells
Prior allogeneic hematopoietic cell transplant.
Patients who have received a prior allogeneic hematopoietic stem cell transplant (HSCT) and who have either rejected their grafts or who have become tolerant of their grafts with no active GVHD requiring immunosuppressive therapy
Preceding allogeneic hematopoietic stem cell transplant (HSCT)
No subjects who have received an allogeneic hematopoietic stem cell transplant are eligible
Received an allogeneic hematopoietic transplant within  months of screening
Patients undergoing haploidentical allogeneic hematopoietic stem cell transplants are not eligible; patients undergoing < / HLA allele matched allogeneic transplant are not eligible
Prior allogeneic transplant for any hematopoietic disorder
Prior allogeneic hematopoietic stem cell transplant.
Subject who has history of organ transplant or allogeneic hematopoietic stem cell transplantation.
Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ?  months.
Patients who have previously undergone allogeneic hematopoietic stem cell transplant will be excluded from this study
Allogeneic hematopoietic stem cell transplant within  days prior to leukapheresis
Prior history of allogeneic hematopoietic stem cell transplant (HSCT).
Recipients of prior allogeneic hematopoietic stem cell transplant (HSCT) with active acute or chronic GVHD
Prior allogeneic hematopoietic stem cell transplant
Prior allogeneic hematopoietic stem cell transplant
Prior allogeneic hematopoietic stem cell transplant.
Prior allogeneic hematopoietic stem cell transplant (HSCT)
Prior allogeneic hematopoietic stem cell transplantation (allogeneic stem cell transplant)
Prior allogeneic hematopoietic stem cell transplant
At least  days after receiving any allogeneic hematopoietic stem cell transplant AND
Previous allogeneic hematopoietic stem cell transplant (HSCT transplant).
Allogeneic hematopoietic stem cell transplant or Donor Lymphocyte Infusion within  days prior to to the first dose of study drug
Prior allogeneic hematopoietic stem cell transplant
Prior allogeneic hematopoietic stem cell transplant within </= months before first dose of study drug (Subjects must have completed immunosuppressive therapy before enrollment.
Prior allogeneic hematopoietic cell transplant
Not currently a candidate for allogeneic hematopoietic stem cell transplant (HSCT).
Previous allogeneic hematopoietic transplant within  days of study enrollment, Active GVHD requiring treatment.
Previous allogeneic hematopoietic transplant within  days. Active GVHD requiring treatment
Any previous allogeneic hematopoietic stem cell transplant.
Patients must have received allogeneic hematopoietic stem cell transplant and be greater than  days post-transplant at the time of registration
Scheduled to undergo an allogeneic hematopoietic stem cell transplant for any cancer or non-cancer illness
Prior allogeneic hematopoietic stem cell transplant (HSCT)
Allogeneic hematopoietic cell transplant recipient
Prior allogeneic hematopoietic cell transplant
Prior allotransplant, including allogeneic hematopoietic cell transplant or solid organ allogeneic transplant
Diagnosis of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for whom an allogeneic hematopoietic stem cell transplant using a reduced intensity conditioning is planned or has been performed and patient is prior to day  post-transplant
Patient must have a diagnosis that is managed with an alternative donor allogeneic hematopoietic cell transplant
Prior allogeneic hematopoietic stem cell transplant.
Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ?  months prior to starting CC-.
